Company Quick10K Filing
Cellect Biotechnology
Closing Price ($) Shares Out (MM) Market Cap ($MM)
$0.00 130 $346
20-F 2019-03-18 Annual: 2018-12-31
20-F 2018-03-19 Annual: 2017-12-31
20-F 2017-03-23 Annual: 2016-12-31

Cellect Biotechnology Financials

APOP Metrics, Comps, Filings

Annual | Quarterly

Business

Our legal and commercial name is Cellect Biotechnology Ltd. We were established as a private company limited by shares under the laws of the State of Israel on August 4, 1986, under the name Montiger Ltd. Between 1986 and 2013, we underwent several name changes, most recently on August 28, 2013, when we changed our name from T.R.F. Capital Ltd. to Cellect Biomed Ltd. On May 16, 2016, we obtained shareholder approval to change our name to Cellect Biotechnology Ltd. We formally changed our name to Cellect Biotechnology Ltd. on July 21, 2016. On July 29, 2016, our ADSs and warrants, commenced trading on the Nasdaq Capital Market under the symbols “APOP” and “APOPW”, respectively. From 1990 to September 3, 2017, our shares were traded on the TASE.

From October 25, 2012 until July 1, 2013, we did not have any business operations, excluding administrative management. On June 30, 2013, a general meeting of our shareholders approved our merger by way of share exchange with Cellect Biotherapeutics Ltd., or Cellect Biotherapeutics. As a result of the merger, which closed on July 1, 2013, Cellect Biotherapeutics became a wholly owned subsidiary and we issued to shareholders of Cellect Biotherapeutics 44,887,373 ordinary shares, options (Series 1) exercisable for 227,358 ordinary shares, and options (Series 2) exercisable for 341,037 ordinary shares (all of such 341,037 options were subsequently exercised into ordinary shares), which constituted approximately 85% of our then outstanding share capital and 85% of our then outstanding share capital on a fully diluted basis.

Cellect Biotherapeutics was established as a private company limited by shares under the State of Israel on June 9, 2011 for the purpose of developing novel and unique technologies that allow the functional selection of stem cells through the substantial reduction of the complications that exist today in acceptable selection methods and increasing the chances of success of stem cell therapies.


Valuation ($MM)

Market Cap, Enterprise Value

Balance Sheet ($MM)

Assets, Stockholders' Equity

Income Statement ($MM Annual)

Revenue, Gross Profit, Net Income

Cash Flow ($MM Annual)

Operating, Investing, Financing

Comps ($'000 TTM) Market Cap Gross Margin EV/EBITDA Ret on Assets Assets Liabilities Revenue G Profit Net Income EBITDA EV
Dusa Pharmaceuticals (DUSA) 551,168 85% 121.8 9% 41,655 11,248 53,863 45,942 3,733 4,289 522,432
AG Mortgage Investment Trust (MITT) 528,703 3.4 1% 3,797,915 3,067,051 0 0 32,986 127,445 435,753
Digital River (DRIV) 469,711 81% 9.2 0% 734,378 377,803 385,810 312,355 0 25,573 236,306
Pinnacle Foods (CIK) 377,837 29% 3.3 9% 6,435,162 4,003,632 3,153,913 910,558 603,685 929,668 3,055,449
Cellect Biotechnology (APOP) 345,599 0% 20,638 0 0 0 0 345,262
Fly Leasing (FLY) 344,131 0% -9.7 -0% 4,226,472 3,524,362 454,473 0 -6,507 -6,507 63,051
Synlogic (SYBX) 282,623 0% -3.3 -22% 214,945 34,122 2,600 0 -47,969 -46,020 153,623
Fronteo (FTEO) 280,038 0% 13,842,552 8,824,725 0 0 0 0 -281,719
Integrated Biopharma (INB) 261,841 12% 88.7 9% 19,790 17,897 49,977 6,221 1,688 3,055 271,019
First California Financial Group (FCAL) 248,137 6.4 0% 1,737,289 1,503,761 0 0 7,149 31,114 198,272
Pingtan Marine Enterprise (PME) 189,732 38% 15.9 5% 361,591 207,133 83,653 31,808 16,881 19,561 311,582
Alliance Healthcare Services (AIQ) 146,154 43% 6.1 3% 653,751 662,695 523,704 225,608 17,692 108,709 665,505
Sterling Real Estate Trust (SRET) 135,372 12% 12.1 3% 701,089 419,313 118,815 14,776 20,354 42,226 509,002
Meridian (MRBK) 115,326 2.8 1% 1,055,906 941,527 0 0 9,119 29,812 84,696
All Soft Gels (ASG) 111,547 71% -81.5 -2,619% 56 716 78 55 -1,463 -1,368 111,520
Newtek Business Services (NEWT) 102,397 50% 14.4 1% 203,186 119,953 38,166 19,019 2,644 6,825 97,995
AquaBounty Technologies (AQB) 61,340 14% -5.2 -32% 36,775 7,056 158 23 -11,942 -10,756 55,565
Arcturus Therapeutics (ARCT) 53,595 0% -4.8 -15% 44,419 38,065 4,350 0 -6,884 -6,712 32,213
Chart Acquisition (CACG) 37,032 -96.2 -1% 29,842 8,652 0 0 -414 -384 36,965
US Gold (USAU) 21,724 -2.5 -86% 8,772 384 0 0 -7,583 -7,147 18,185

Balance Sheet ($'000)2017-12-312018-12-31
Cash305337
Accounts Receivable
Inventory
PP&E
Assets30,37320,638
Accounts Payable
Long-Term Debt
Liabilities
Stockholders' Equity
Income Statement ($'000)2017-12-312018-12-31
Revenue
Cost of Revenue
Gross Profit
R&D3,31813,513
SG&A3,4443,730
Tax
Net Income-8,141-20,113
Cash Flow ($'000)2017-12-312018-12-31
Cash Operating
Cash Investing
Cash Financing